Idéal Investisseur
Français English
CAC 40 : Market closed
8 365,01 pts
-0.05%


Last updated : 16/11/2026 - 17h14
🏠 Home   ➤    Stock news

Valneva shares rebound and climb into the top tier of the SBF 120

The Lyon-based vaccine maker recovers sharply as the close approaches, while the Paris market stalls. After a decline at the end of last week, the stock regains ground and moves back into the top of its index, as the company takes part in a healthcare conference.


Valneva shares rebound and climb into the top tier of the SBF 120

A rebound that brings the stock back above its 20-day moving average and places it among the best performers of the SBF 120

Valneva shares gain 1.64% to €2.61 and rank among the strongest gainers of the SBF 120, which remains flat, while the CAC 40 is virtually unchanged. This move erases the decline of the last session: the day before this Monday, the weekend had closed the stock exchange, and on Friday the stock had lost 2.5% after falling back below its 50-day moving average.

The price is now 3.98% above the 20-day moving average, at €2.51, but remains 0.76% below the 50-day moving average, at €2.63. The resistance level at €2.68 is getting closer, a level already crossed on November 12 before the stock pulled back.

Over one week, the stock rises 4.32%, extending a rebound that began at the start of the month. Over three months, it still falls 13%, and the 200-day moving average at €2.85 remains more than 8% above the current price.

New data on Ixchiq and Lyme disease vaccine on the company's agenda

On November 10, Valneva released new data on its chikungunya vaccine: the seroresponse remains at 94% five years after a single dose. On November 9, the group had also published positive phase 2 results for its candidate against shigellosis. The company is participating today in the Jefferies Global Healthcare Conference.

When it published its first-half 2026 results on August 13, the company confirmed its outlook for the year, while pointing to the lasting impact of the geopolitical context on travel. It also expected regulatory decisions on its Lyme disease candidate within the following twelve months.

Sanofi, another healthcare stock, gains 0.95% this Monday and is up 22.92% over one month.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 65,8 millions d'euros
  • Quarterly revenue: 65,8 millions d'euros
  • Revenue growth: -32,6 %
  • EBITDA: -39,8 millions d'euros
  • EBITDA margin: -60,4 %
  • Net income: -63,3 millions d'euros
Guidance from the release
  • Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
  • Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
  • Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
  • Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
  • Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
  • Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
  • Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
  • Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours